NCT Stage Cell type Study design Phase Participants Route Intervention Findings NCT01297218 Completed Human UCB-MSCs Open-label, single-center study 1 9 1 single I.C. infusion 250,000 UCB-MSCs per 5 μ L per 1 entry site, 3 million cells per brain.μ L per 1 entry site, 6 million cells per brain. The stereotactic injection of UCB-MSCs into the hippocampus and precuneus is feasible, safe, and well tolerated. However, a single injection of UCB-MSCs was not effective in altering the AD pathophysiological process [54 , 55 ]. NCT01696591 Unknown Human UCB-MSCs Long-term follow-up study of NCT01297218 Same as NCT01297218 [56 ] NCT02054208 Completed Human UCB-MSCs Double-blind, single-center study 1/2a 45 3 I.V.T. infusions Not yet published results [57 ]. NCT03172117 Recruiting Human UCB-MSCs Long-term follow-up study of NCT02054208 Same as NCT02054208 [61 ] NCT03117738 Completed Autologous human AD-MSCs Randomized, double-blind, placebo-controlled, parallel-group comparison study 1/2 21 9 I.V. infusions Not yet published results [58 ]. NCT04228666 Withdrawn Autologous human AD-MSCs Open-label, nonrandomized study 1/2a 24 4 I.V. infusions N/A [59 ] NCT02600130 Active, not recruiting LMSCs Randomized, placebo-controlled study 1 33 1 single I.V. infusion 20 million LMSCs N/A [60 ] NCT04855955 Available Autologous human AD-MSCs Single patient emergency expanded access study N/A 1 N/A N/A N/A [62 ] NCT02833792 Recruiting Human MSCs Multicenter, randomized, single-blind, placebo-controlled, crossover study 2a 40 1 single I.V. infusion 1.5 million MSCs per kilogram body weight N/A [63 ] NCT04040348 Recruiting Allogeneic human UCB-MSCs Prospective open-label study 1 6 4 I.V. infusions 100 million UCB-MSCs N/A [64 ] NCT04388982 Recruiting Allogenic AD-MSCs-Exos Single-center, open-label study 1/2 9 24 nasal drip infusions. 5 μ g MSCs-Exos/1 mLμ g MSCs-Exos/1 mLμ g MSCs-Exos/1 mL N/A [65 ] NCT02899091 Recruiting P-MSCs Randomized, double-blind, placebo-controlled study 1/2a 24 1 and 2 I.V. infusions. N/A [66 ] NCT04684602 Recruiting Human UCB-MSCs Multicenter, prospective, open-label clinical study 1/2 5,000 1 single infusion via condition-specific route of administration. N/A N/A [67 ] NCT04482413 Not yet recruiting Autologous AD-MSCs Randomized, double-blind, active-controlled study 2b 80 4 I.V. infusions N/A [68 ] NCT01547689 Unknown Human UCB-MSCs Open-label, single-center, self-control study 1/2 30 8 I.V. infusions 20 million UCB-MSCs ( N/A [69 ] NCT02672306 Unknown Human UCB-MSCs Multicenter, randomized, double-blind, placebo-controlled study 1/2 16 8 I.V. infusions 20 million UCB-MSCs per subject ( N/A [70 ]
